Disclosures for "A Phase 1, Open-label, Exploratory, Fixed-sequence, Pharmacokinetic Single Ascending Dose Study of IVL3004 Versus VIVITROL® (Naltrexone) Long-acting Injectable (LAI) in Healthy Subjects"